Sepracor Resubmits Estorra NDA; Expected Approval Pushed To Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects FDA will take six months to review the eszopiclone resubmission. Sepracor had earlier expressed optimism about a two-month review, which would have set an approval target for the sleep agent around mid-year.